By Puyaan Singh

Jan 7 (Reuters) - Omeros ( OMER ) will price its

recently approved drug for a life-threatening transplant

complication in adults and children aged two and older ‌at

$36,000 per single-dose vial, CEO Gregory Demopulos said ​on a

call with analysts on Wednesday.

Shares of ‍the company were up 6.6% ⁠in ⁠extended trade.

The drug, sold under the brand name Yartemlea, ‌treats

transplant-associated thrombotic microangiopathy (TA-TMA), ​a

serious complication that can arise after a stem cell

transplant, particularly when ⁠donor cells are ‍used.

Yartemlea, a ​monoclonal antibody drug, works by blocking the

MASP-2 protein that plays a key ‍role in the immune system.

Last month, Yartemlea became the first treatment to be

approved for TA-TMA.

"Across the pivotal clinical trial ... median utilization

was 8 to 10 vials ​per ‍treatment course," Demopulos said on the

call, adding that around "11,000 allogeneic (donor cell)

transplants ​are performed each year in the United States."

"TA-TMA develops in up to 56% of allogeneic transplant

recipients," he added.

The company said it expects a decision from the European

medicines regulator in ​mid-2026.

The company initiated the commercial launch of Yartemlea in

the U.S. on January 2, Demopulos said.